## Simani Gaseitsiwe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11569301/publications.pdf

Version: 2024-02-01

706676 536525 2,663 30 14 29 citations g-index h-index papers 32 32 32 4530 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 2022, 603, 679-686.	13.7	1,210
2	HIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana. Journal of Antimicrobial Chemotherapy, 2022, 77, 1385-1395.	1.3	7
3	Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana. AIDS Research and Human Retroviruses, 2021, 37, 16-23.	0.5	1
4	Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 335-347.	0.4	8
5	Limited HIV-1 Subtype C nef 3′PPT Variation in Combination Antiretroviral Therapy NaÃ⁻ve and Experienced People Living with HIV in Botswana. Pathogens, 2021, 10, 1027.	1.2	2
6	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
7	Genome-wide association study reveals genetic variants associated with HIV-1C infection in a Botswana study population. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2107830118.	3.3	3
8	Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. Journal of Infectious Diseases, 2020, 222, 1670-1680.	1.9	12
9	In Silico Prediction of Human Leukocytes Antigen (HLA) Class II Binding Hepatitis B Virus (HBV) Peptides in Botswana. Viruses, 2020, 12, 731.	1.5	6
10	Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. New England Journal of Medicine, 2019, 381, 230-242.	13.9	163
11	Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana. Aids, 2019, 33, 1073-1082.	1.0	11
12	Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination. Medicine (United States), 2019, 98, e18014.	0.4	1
13	Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana. AIDS Research and Human Retroviruses, 2018, 34, 667-671.	0.5	11
14	Genome-Wide Analyses Reveal Gene Influence on HIV Disease Progression and HIV-1C Acquisition in Southern Africa. AIDS Research and Human Retroviruses, 2017, 33, 597-609.	0.5	14
15	Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable. Journal of Clinical Microbiology, 2016, 54, 3050-3055.	1.8	67
16	H3ABioNet, a sustainable pan-African bioinformatics network for human heredity and health in Africa. Genome Research, 2016, 26, 271-277.	2.4	94
17	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	6.0	361
18	Whole CMV Proteome Pattern Recognition Analysis after HSCT Identifies Unique Epitope Targets Associated with the CMV Status. PLoS ONE, 2014, 9, e89648.	1.1	16

#	Article	IF	CITATIONS
19	The preferential selection of K65R in HIV-1 subtype C is attenuated by nucleotide polymorphisms at thymidine analogue mutation sites. Journal of Antimicrobial Chemotherapy, 2013, 68, 2192-6.	1.3	4
20	Infant Feeding Practices were not Associated with Breast Milk HIV-1 RNA Levels in a Randomized Clinical Trial in Botswana. AIDS and Behavior, 2012, 16, 1260-1264.	1.4	7
21	Peptide Microarray-Based Identification of <i>Mycobacterium tuberculosis</i> Epitope Binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Vaccine Journal, 2010, 17, 168-175.	3.2	41
22	Humoral â€~reactome' profiles using peptide microarray chips. Trends in Immunology, 2010, 31, 399-400.	2.9	13
23	Major Histocompatibility Complex Class II Molecule-Human Immunodeficiency Virus Peptide Analysis Using a Microarray Chip. Vaccine Journal, 2009, 16, 567-573.	3.2	10
24	Pattern Recognition in Pulmonary Tuberculosis Defined by High Content Peptide Microarray Chip Analysis Representing 61 Proteins from M. tuberculosis. PLoS ONE, 2008, 3, e3840.	1.1	67
25	The Reverse Transcriptase 67N 70R 215Y Genotype Is the Predominant TAM Pathway Associated with Virologic Failure among HIV Type 1C-Infected Adults Treated with ZDV/ddI-Containing HAART in Southern Africa. AIDS Research and Human Retroviruses, 2007, 23, 868-878.	0.5	65
26	Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. Aids, 2006, 20, 1281-1288.	1.0	82
27	High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based Regimens. Antimicrobial Agents and Chemotherapy, 2006, 50, 4182-4185.	1.4	104
28	Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen. Antimicrobial Agents and Chemotherapy, 2006, 50, 2210-2213.	1.4	23
29	Major Histocompatibility Complex Class II (HLA-DRB and -DQB) Allele Frequencies in Botswana: Association with Human Immunodeficiency Virus Type 1 Infection. Vaccine Journal, 2005, 12, 1020-1028.	3.2	26
30	Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature, 0, , .	13.7	61